News | Radiation Dose Management | August 14, 2018

Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence

Partnership will work to reduce variability and improve quality, safety and efficiency of care around radiation dose management

Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence

August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of artificial intelligence (AI) process and workflow solutions. The Imalogix Platform gives healthcare organizations the tools to understand and manage the process, quality and safety related to diagnostic imaging and interventional procedures, and meet evolving regulatory standards surrounding radiation dose management with ease.

The commercial partnership combines Guerbet's capabilities in diagnostic and interventional imaging with the cloud-based human and machine-intelligence capabilities of Imalogix to proactively identify areas that impact care delivery. The goal is to reduce variability and improve the quality, safety and efficiency of care around radiation dose management.

The Imalogix self-learning neural network enables organizations to understand and benchmark in real-time best practices from the mass learnings across a network of providers to drive continuous improvement. Deep learning recommendations highlight where and how changes can be made to enable organizations to proactively change behavior down to the scanner, protocol and operator level. Insights into procedure length, utilization and workflow help organizations understand how to become more efficient and optimize patient flow.

For more information: www.guerbet.com, www.imalogix.com

Related Content

Cina Chest is part of Avicenna’s CINA family of AI tools that support the treatment of emergencies, including CINA HEAD, its FDA-cleared and CE-Marked solution that supports the detection and triage of stroke and neurovascular emergencies.
News | Artificial Intelligence | June 03, 2021
June 3, 2021 — Medical imaging AI specialist Avicenna.AI announced
Chest X-rays used in the COVID-Net study show differing infection extent and opacity in the lungs of COVID-19 patients. Image courtesy of University of Waterloo

Chest X-rays used in the COVID-Net study show differing infection extent and opacity in the lungs of COVID-19 patients. Image courtesy of University of Waterloo

News | Coronavirus (COVID-19) | June 03, 2021
June 3, 2021 — Artificial intelligence
International medical imaging IT and cybersecurity company Sectra will install its solution for digital pathology at Institut Curie, one of the most recognized and prestigious cancer centers in France.
News | Enterprise Imaging | May 24, 2021
May 24, 2021 — International medical imaging IT and cybersecurity company ...
Carestream selects HPE GreenLake Cloud Services to power transformative artificial intelligence-as-a-service (AIaas)
News | Artificial Intelligence | May 20, 2021
May 20, 2021 — Carestream Health is transforming and accelerating the way it develops and delivers...
The Healthcare Information and Management Systems Society, Inc. (HIMSS) 2021 Conference, scheduled for August 9-13 in Las Vegas, will be one of the first to take a step back to normalcy

Getty Images

News | HIMSS | May 17, 2021
May 17, 2021 — It looks like in-person conferences are making a comeback.
Artificial intelligence (AI)-driven healthcare has potential to transform medical decision-making and treatment, but AI algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients. In JAMA Network Open, Regenstrief Institute President Peter Embí, M.D., calls for algorithmovigilance (a term he coined for scientific methods and activities relating to evaluation, monitoring, understanding and prevention of adverse effects of algorithms in healthcare) to address

Artificial intelligence (AI)-driven healthcare has potential to transform medical decision-making and treatment, but AI algorithms must be thoroughly tested and continuously monitored to avoid unintended consequences to patients. In JAMA Network Open, Regenstrief Institute President Peter Embí, M.D., calls for algorithmovigilance (a term he coined for scientific methods and activities relating to evaluation, monitoring, understanding and prevention of adverse effects of algorithms in healthcare) to address inherent biases in healthcare algorithms and their deployment. Image courtesy of Regenstrief Institute

News | Artificial Intelligence | May 14, 2021
May 14, 2021 — Artificial intelligence